Chai Discovery closed a $130 million Series B to accelerate its Chai‑2 AI platform for de novo antibody design, citing double‑digit success rates in early wet‑lab validation and expanded ambitions to deliver full‑length therapeutic mAbs. The funding will scale discovery throughput and commercial partnerships. Valinor, an AI/multiomics startup, raised $13 million in seed financing to develop machine‑learning models that match multiomics signatures to clinical outcomes and guide trial design. Both financings reflect investor appetite for ML tools that compress discovery timelines and increase signal detection in translational pipelines.